The use of bortezomib, a proteasome inhibitor, down-regulates pro-fibrotic miR-21 (up-regulated in fibroblasts of SSc patients) and blocks TGF-β-induced fibrosis in an SSc animal model [138]. This evidence concerns the gene TGFB1 and systemic sclerosis.